Who are Oral P2Y12 receptor blocker's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): P2Y12 Receptor Antagonist, Patent clopidogrel, Clopidogrel active metabolite, Clopidogrel reloading, half-dose ticagrelor, low-dose ticagrelor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-p2y12-receptor-blocker.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oral P2Y12 receptor blocker — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral P2Y12 receptor blocker (Oral P2Y12 receptor blocker) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class. Area: Cardiovascular.

marketed Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class P2Y12 adenosine diphosphate receptor on platelet surface Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Oral P2Y12 receptor blocker (Oral P2Y12 receptor blocker) — Italian Society of Invasive Cardiology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oral P2Y12 receptor blocker TARGET	Oral P2Y12 receptor blocker	Italian Society of Invasive Cardiology	marketed	Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class	P2Y12 adenosine diphosphate receptor on platelet surface
P2Y12 Receptor Antagonist	P2Y12 Receptor Antagonist	Fu Wai Hospital, Beijing, China	marketed	P2Y12 receptor antagonist	P2Y12 receptor
Patent clopidogrel	Patent clopidogrel	Hospital Central San Luis Potosi, Mexico	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Clopidogrel active metabolite	Clopidogrel active metabolite	University of Florida	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Clopidogrel reloading	Clopidogrel reloading	University of Pecs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
half-dose ticagrelor	half-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	marketed	P2Y12 receptor antagonist	P2Y12
low-dose ticagrelor	low-dose ticagrelor	First Affiliated Hospital of Harbin Medical University	marketed	P2Y12 receptor antagonist	P2Y12

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class class)

Italian Society of Invasive Cardiology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral P2Y12 receptor blocker — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-p2y12-receptor-blocker. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab